

**Supplementary table 1 – Safety outcomes in the MRF cohort**

	Dapagliflozin N=5104		Placebo N=5073		<b>HR (95% CI)</b>	<b>Cox p-value</b>
	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>		
<b>Outcome</b>						
Major hypoglycemic event	24	0.5%	44	0.9%	0.53 (0.32-0.87)	0.011
Diabetic Ketoacidosis Definite or Probable	16	0.3%	6	0.1%	2.56 (1.00-6.54)	0.050
Amputation	42	0.8%	54	1.1%	0.77 (0.51-1.15)	0.200
Fracture	262	5.1%	227	4.5%	1.15 (0.96-1.37)	0.128
Symptoms of volume depletion	82	1.6%	78	1.5%	1.02 (0.75-1.39)	0.921
Genital infections	51	1.0%	3	0.1%	16.72 (5.22-53.56)	<0.001
Urinary tract infection	70	1.4%	80	1.6%	0.84 (0.61-1.16)	0.301
Cancer	294	5.8%	281	5.5%	1.04 (0.88-1.22)	0.668
Acute kidney injury	59	1.2%	64	1.3%	0.89 (0.62-1.26)	0.505

Legend: Genital and urinary infections considered were either serious (2 in each arm) or led to discontinuation of study drug.